Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (23): 4349-4353.doi: 10.3969/j.issn.1673-8225.2012.23.033032

Previous Articles     Next Articles

Research progress of stem cell therapy for type 1 diabetes mellitus

Hu Mei-jun, Pan Xing-hua, Pang Rong-qing, Cai Xue-min   

  1. Research Center of Stem Cells and Tissue and Organ Engineering, Kunming General Hospital in Chengdu Military Area Command of Chinese PLA, Clinical College, Kunming General Hospital of Kunming Medical College, Kunming 650032, Yunnan Province, China
  • Received:2011-10-30 Revised:2011-11-17 Online:2012-06-03 Published:2013-11-06
  • About author:Hu Mei-jun★, Master, Research Center of Stem Cells and Tissue and Organ Engineering, Kunming General Hospital in Chengdu Military Area Command of Chinese PLA, Clinical College, Kunming General Hospital of Kunming Medical College, Kunming 650032, Yunnan Province, China 119589025@qq.com

PDF

630

Abstract:

BACKGROUND: The possible effective way for the treatment of type 1 diabetes mellitus is to rebuild the secreting system of insulin through pancreatic or pancreatic islet transplantation. However, limited donors and rejection after transplantation often lead to failed treatment.
OBJECTIVE: To summarize the study progress in embryonic stem cells, somatic stem cells and induced pluripotent stem cells for the treatment of type 1 diabetes mellitus.
METHODS: Articles addressing stem cells for the treatment of type 1 diabetes mellitus were retrieved online in CNKI database and PubMed database from January 2008 to December 2011 with the key words of “embryonic stem cells, somatic stem cells, induced pluripotent stem cells, type 1 diabetes mellitus” in Chinese and English in the title and abstract. The articles related to stem cells for the treatment of type 1 diabetes were included. For the articles in the same field, those published recently or in the authorize journals were preferred. A total of 128 literatures were obtained, and 33 documents of them were involved for review according to the inclusion criteria.
RESULTS AND CONCLUSION: Recently, different sources of stem cells could be induced into insulin-producing cells in vivo or in vitro, and the induced cells were used in the treatment of animal model with type 1 diabetes. It showed certaub therapeutic efficacy and even made recipient’s blood sugar level returned to normal. But controversy exists regarding whether stem cells took part in islet cell regeneration or repair.

CLC Number: